{"transactions":[{"id":697716,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Line of Credit Convertible Notes","published_at":"2026-08-04T11:52:26.000Z","date":"2026-07-31","kind":"exercise","planned":false,"acquired":false,"price":10331275,"reported_value":10331275,"ownership":{"direct":false,"nature":"Richard E. Uihlein Stock Trust"},"footnotes":[{"field":"reported_value","element":"transactionTotalValue","label":"F2","text":"Consists of $10,000,000 of principal and $331,275 of accrued interest."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Consists of $10,000,000 of principal and $331,275 of accrued interest."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Line of Credit Convertible Notes are exercisable upon issuance when the issuer draws on the Line of Credit.  Notes were issued on December 19, 2022; March 31, 2023; June 30, 2023; December 29, 2023; March 29, 2024; June 28, 2024; September30, 2024; April 30, 2025; June 30, 2025 and December 31, 2025. There was no expiration date; however, the maturity date of all Line of Credit Convertible Notes was June 30, 2027."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Line of Credit Convertible Notes are exercisable upon issuance when the issuer draws on the Line of Credit.  Notes were issued on December 19, 2022; March 31, 2023; June 30, 2023; December 29, 2023; March 29, 2024; June 28, 2024; September30, 2024; April 30, 2025; June 30, 2025 and December 31, 2025. There was no expiration date; however, the maturity date of all Line of Credit Convertible Notes was June 30, 2027."}],"balance_after":0,"derivative":{"exercise_price":4.05,"exercise_date":"2025-12-31","expiration_date":"2027-06-30","underlying":"Common Stock","underlying_shares":2550932},"source":{"system":"sec-edgar","filing":"0001133416-26-000065","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000065/form4.xml","form_type":"4"}},{"id":697715,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Line of Credit Convertible Notes","published_at":"2026-08-04T11:52:26.000Z","date":"2026-07-31","kind":"exercise","planned":false,"acquired":false,"price":95475705,"reported_value":95475705,"ownership":{"direct":false,"nature":"Richard E. Uihlein Stock Trust"},"footnotes":[{"field":"reported_value","element":"transactionTotalValue","label":"F1","text":"Consists of $91,000,000 in principal and $14,475,705 in accrued interest."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Consists of $91,000,000 in principal and $14,475,705 in accrued interest."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Line of Credit Convertible Notes are exercisable upon issuance when the issuer draws on the Line of Credit.  Notes were issued on December 19, 2022; March 31, 2023; June 30, 2023; December 29, 2023; March 29, 2024; June 28, 2024; September30, 2024; April 30, 2025; June 30, 2025 and December 31, 2025. There was no expiration date; however, the maturity date of all Line of Credit Convertible Notes was June 30, 2027."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Line of Credit Convertible Notes are exercisable upon issuance when the issuer draws on the Line of Credit.  Notes were issued on December 19, 2022; March 31, 2023; June 30, 2023; December 29, 2023; March 29, 2024; June 28, 2024; September30, 2024; April 30, 2025; June 30, 2025 and December 31, 2025. There was no expiration date; however, the maturity date of all Line of Credit Convertible Notes was June 30, 2027."}],"balance_after":0,"derivative":{"exercise_price":3,"exercise_date":"2022-12-19","expiration_date":"2027-06-30","underlying":"Common Stock","underlying_shares":31825235},"source":{"system":"sec-edgar","filing":"0001133416-26-000065","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000065/form4.xml","form_type":"4"}},{"id":697714,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-04T11:52:26.000Z","date":"2026-07-31","kind":"exercise","planned":false,"acquired":true,"shares":2550932,"price":4.05,"value":10331274.6,"ownership":{"direct":false,"nature":"Richard E. Uihlein Stock Trust"},"balance_after":44713843,"source":{"system":"sec-edgar","filing":"0001133416-26-000065","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000065/form4.xml","form_type":"4"}},{"id":697713,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-04T11:52:26.000Z","date":"2026-07-31","kind":"exercise","planned":false,"acquired":true,"shares":31825235,"price":3,"value":95475705.0,"ownership":{"direct":false,"nature":"Richard E. Uihlein Stock Trust"},"balance_after":42162911,"source":{"system":"sec-edgar","filing":"0001133416-26-000065","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000065/form4.xml","form_type":"4"}},{"id":708295,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock option (right to buy)","published_at":"2026-07-16T21:39:50.000Z","date":"2026-07-14","kind":"exercise","planned":true,"acquired":false,"shares":16250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vested at a rate of twenty five percent or 16,250 options on each of June 30, 2026; December 31, 2026; June 30, 2027; and December 31, 2027."}],"balance_after":48750,"derivative":{"exercise_price":3.04,"exercise_date":"2026-06-30","expiration_date":"2036-01-16","underlying":"Common Stock","underlying_shares":16250},"source":{"system":"sec-edgar","filing":"0001133416-26-000063","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000063/form4.xml","form_type":"4"}},{"id":708294,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-07-16T21:39:50.000Z","date":"2026-07-14","kind":"sale","planned":true,"acquired":false,"shares":16250,"price":5.1252,"value":83284.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple transactions at prices ranging from $5.00 to $5.32. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001133416-26-000063","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000063/form4.xml","form_type":"4"}},{"id":708293,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-07-16T21:39:50.000Z","date":"2026-07-14","kind":"exercise","planned":true,"acquired":true,"shares":16250,"price":3.04,"value":49400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026"}],"balance_after":16250,"source":{"system":"sec-edgar","filing":"0001133416-26-000063","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000063/form4.xml","form_type":"4"}},{"id":723052,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-30T23:24:12.000Z","date":"2026-06-29","kind":"exercise","planned":true,"acquired":false,"shares":22268,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29. 2025, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vested 100% on December 31, 2025."}],"balance_after":30000,"derivative":{"exercise_price":1.23,"exercise_date":"2025-12-31","expiration_date":"2035-01-23","underlying":"Common Stock","underlying_shares":22268},"source":{"system":"sec-edgar","filing":"0001133416-26-000061","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000061/form4.xml","form_type":"4"}},{"id":723051,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-30T23:24:12.000Z","date":"2026-06-26","kind":"exercise","planned":true,"acquired":false,"shares":7732,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29. 2025, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vested 100% on December 31, 2025."}],"balance_after":52268,"derivative":{"exercise_price":1.23,"exercise_date":"2025-12-31","expiration_date":"2035-01-23","underlying":"Common Stock","underlying_shares":7732},"source":{"system":"sec-edgar","filing":"0001133416-26-000061","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000061/form4.xml","form_type":"4"}},{"id":723050,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T23:24:12.000Z","date":"2026-06-29","kind":"sale","planned":true,"acquired":false,"shares":22268,"price":5.04,"value":112230.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29. 2025, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The shares were sold in multiple transactions at prices ranging from $5.00 to $5.12. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":6500,"source":{"system":"sec-edgar","filing":"0001133416-26-000061","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000061/form4.xml","form_type":"4"}},{"id":723049,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T23:24:12.000Z","date":"2026-06-29","kind":"exercise","planned":true,"acquired":true,"shares":22268,"price":1.23,"value":27389.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29. 2025, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025"}],"balance_after":28768,"source":{"system":"sec-edgar","filing":"0001133416-26-000061","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000061/form4.xml","form_type":"4"}},{"id":723048,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T23:24:12.000Z","date":"2026-06-26","kind":"sale","planned":true,"acquired":false,"shares":7732,"price":5,"value":38660.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29. 2025, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple transactions at prices ranging from $5.00 to $5.01. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":6500,"source":{"system":"sec-edgar","filing":"0001133416-26-000061","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000061/form4.xml","form_type":"4"}},{"id":723047,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T23:24:12.000Z","date":"2026-06-26","kind":"exercise","planned":true,"acquired":true,"shares":7732,"price":1.23,"value":9510.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29. 2025, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025"}],"balance_after":14232,"source":{"system":"sec-edgar","filing":"0001133416-26-000061","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000061/form4.xml","form_type":"4"}},{"id":723046,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-06-30T23:23:14.000Z","date":"2026-06-29","kind":"exercise","planned":true,"acquired":false,"shares":47467,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vested at a rate of twenty five percent or 25,000 options on each of October 31, 2024, January 31, 2025, April 30, 2025 and July 31, 2025."}],"balance_after":0,"derivative":{"exercise_price":2.5,"exercise_date":"2025-07-31","expiration_date":"2034-08-01","underlying":"Common Stock","underlying_shares":47467},"source":{"system":"sec-edgar","filing":"0001133416-26-000059","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000059/form4.xml","form_type":"4"}},{"id":723045,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-06-30T23:23:14.000Z","date":"2026-06-26","kind":"exercise","planned":true,"acquired":false,"shares":2533,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vested at a rate of twenty five percent or 25,000 options on each of October 31, 2024, January 31, 2025, April 30, 2025 and July 31, 2025."}],"balance_after":47467,"derivative":{"exercise_price":2.5,"exercise_date":"2025-04-30","expiration_date":"2034-08-01","underlying":"Common Stock","underlying_shares":2533},"source":{"system":"sec-edgar","filing":"0001133416-26-000059","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000059/form4.xml","form_type":"4"}},{"id":723044,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock option (right to buy)","published_at":"2026-06-30T23:23:14.000Z","date":"2026-06-26","kind":"exercise","planned":true,"acquired":false,"shares":2037,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vested at a rate of one-third or 50,000 options on each of March 11, 2025, March 11, 2026 and March 11, 2027."}],"balance_after":100000,"derivative":{"exercise_price":2.2,"exercise_date":"2025-03-11","expiration_date":"2034-03-20","underlying":"Common Stock","underlying_shares":2037},"source":{"system":"sec-edgar","filing":"0001133416-26-000059","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000059/form4.xml","form_type":"4"}},{"id":723043,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-06-30T23:23:14.000Z","date":"2026-06-29","kind":"sale","planned":true,"acquired":false,"shares":47467,"price":5.04,"value":239233.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026"},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The shares were sold in multiple transactions at prices ranging from $5.00 to $5.13. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001133416-26-000059","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000059/form4.xml","form_type":"4"}},{"id":723042,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-06-30T23:23:14.000Z","date":"2026-06-29","kind":"exercise","planned":true,"acquired":true,"shares":47467,"price":2.5,"value":118667.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026"}],"balance_after":47467,"source":{"system":"sec-edgar","filing":"0001133416-26-000059","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000059/form4.xml","form_type":"4"}},{"id":723041,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-06-30T23:23:14.000Z","date":"2026-06-26","kind":"sale","planned":true,"acquired":false,"shares":2533,"price":5,"value":12665.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple transactions at prices ranging from $5.00 to $5.01. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001133416-26-000059","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000059/form4.xml","form_type":"4"}},{"id":723040,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-06-30T23:23:14.000Z","date":"2026-06-26","kind":"exercise","planned":true,"acquired":true,"shares":2533,"price":2.5,"value":6332.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026"}],"balance_after":2533,"source":{"system":"sec-edgar","filing":"0001133416-26-000059","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000059/form4.xml","form_type":"4"}},{"id":723039,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-06-30T23:23:14.000Z","date":"2026-06-26","kind":"sale","planned":true,"acquired":false,"shares":2037,"price":5,"value":10185.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple transactions at prices ranging from $5.00 to $5.01. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001133416-26-000059","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000059/form4.xml","form_type":"4"}},{"id":723038,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-06-30T23:23:14.000Z","date":"2026-06-26","kind":"exercise","planned":true,"acquired":true,"shares":2037,"price":2.2,"value":4481.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026"}],"balance_after":2037,"source":{"system":"sec-edgar","filing":"0001133416-26-000059","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000059/form4.xml","form_type":"4"}},{"id":726731,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock option (right to buy)","published_at":"2026-06-25T20:06:15.000Z","date":"2026-06-23","kind":"exercise","planned":true,"acquired":false,"shares":7557,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vested as follows: 16,250 on each of June 30, 2025, December 31, 2025, June 30, 2026, and December 31, 2026."}],"balance_after":32500,"derivative":{"exercise_price":1.23,"exercise_date":"2025-12-31","expiration_date":"2035-01-23","underlying":"Common Stock","underlying_shares":7557},"source":{"system":"sec-edgar","filing":"0001133416-26-000057","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000057/form4.xml","form_type":"4"}},{"id":726730,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-06-25T20:06:15.000Z","date":"2026-06-23","kind":"sale","planned":true,"acquired":false,"shares":7557,"price":3.14,"value":23728.98,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple transactions at prices ranging from $3.10 to $3.17. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001133416-26-000057","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000057/form4.xml","form_type":"4"}},{"id":726729,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-06-25T20:06:15.000Z","date":"2026-06-23","kind":"exercise","planned":true,"acquired":true,"shares":7557,"price":1.23,"value":9295.11,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026"}],"balance_after":7557,"source":{"system":"sec-edgar","filing":"0001133416-26-000057","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000057/form4.xml","form_type":"4"}},{"id":760565,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock option (right to buy)","published_at":"2026-05-28T13:13:05.000Z","date":"2026-05-26","kind":"exercise","planned":true,"acquired":false,"shares":568,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vest as follows: 16,250  on each of June 30, 2025, December 31, 2025, June 30, 2026, and December 31, 2026."}],"balance_after":40057,"derivative":{"exercise_price":1.23,"exercise_date":"2025-12-31","expiration_date":"2035-01-23","underlying":"Common Stock","underlying_shares":568},"source":{"system":"sec-edgar","filing":"0001133416-26-000055","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000055/form4.xml","form_type":"4"}},{"id":760564,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-05-28T13:13:05.000Z","date":"2026-05-26","kind":"sale","planned":true,"acquired":false,"shares":568,"price":3.1004,"value":1761.0272,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple transactions at prices ranging from $3.00 to $3.01. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001133416-26-000055","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000055/form4.xml","form_type":"4"}},{"id":760563,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-05-28T13:13:05.000Z","date":"2026-05-26","kind":"exercise","planned":true,"acquired":true,"shares":568,"price":1.23,"value":698.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026"}],"balance_after":568,"source":{"system":"sec-edgar","filing":"0001133416-26-000055","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000055/form4.xml","form_type":"4"}},{"id":838856,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":60147,"kind":"person","name":"Brem Henry","position":1,"cik":"0001387877","reported_name":"Brem Henry","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2026-03-17T13:46:55.000Z","date":"2026-03-12","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest 100% on December 31, 2026."}],"balance_after":60000,"derivative":{"exercise_price":3.16,"expiration_date":"2036-03-12","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001133416-26-000053","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000053/form4.xml","form_type":"4"}},{"id":914758,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":67287,"kind":"person","name":"ELDRED KARY","position":1,"cik":"0001543425","reported_name":"ELDRED KARY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-09T21:25:19.000Z","date":"2026-02-06","kind":"purchase","planned":false,"acquired":true,"shares":300,"price":2.7,"value":810.0,"ownership":{"direct":true},"balance_after":65682,"source":{"system":"sec-edgar","filing":"0001133416-26-000048","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000048/form4.xml","form_type":"4"}},{"id":933613,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock option (right to buy)","published_at":"2026-01-22T19:11:05.000Z","date":"2026-01-16","kind":"grant","planned":false,"acquired":true,"shares":91000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"shares","element":"transactionShares","label":"F3","text":"The original Form 4 filed had an incorrect number of common stock options.   This amendment presents the correct number of common stock options granted."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest as follows: 25% on each of June 30, 2026? December 31, 2026? June 30, 2027? and December 31, 2027."}],"balance_after":91000,"derivative":{"exercise_price":3.04,"expiration_date":"2036-01-16","underlying":"Common Stock","underlying_shares":91000},"source":{"system":"sec-edgar","filing":"0001133416-26-000046","document":"form4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000046/form4a.xml","form_type":"4/A","original_submission_date":"2026-01-21"}},{"id":934881,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":12503,"kind":"person","name":"CARSON BENJAMIN SR","position":1,"cik":"0000017940","reported_name":"CARSON BENJAMIN SR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2026-01-21T22:03:54.000Z","date":"2026-01-16","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest 100% on December 31, 2026."}],"balance_after":60000,"derivative":{"exercise_price":3.04,"expiration_date":"2036-01-16","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001133416-26-000043","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/17940/000113341626000043/form4.xml","form_type":"4"}},{"id":934511,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69097,"kind":"person","name":"Zordani Richard A. Jr.","position":1,"cik":"0001827180","reported_name":"Zordani Richard A. Jr.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2026-01-21T21:50:50.000Z","date":"2026-01-16","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest 100% on December 31, 2026."}],"balance_after":60000,"derivative":{"exercise_price":3.04,"expiration_date":"2036-01-16","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001133416-26-000040","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000040/form4.xml","form_type":"4"}},{"id":934510,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-01-21T21:50:15.000Z","date":"2026-01-16","kind":"grant","planned":true,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The Restricted Stock Units, if vested, convert into Common Stock on a one for one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted Stock Units vest 100% on the earlier of December 31, 2026 or signing of a partnership agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted Stock Units vest 100% on the earlier of December 31, 2026 or signing of a partnership agreement."}],"balance_after":100000,"derivative":{"underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001133416-26-000038","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000038/form4.xml","form_type":"4"}},{"id":934509,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock option (right to buy)","published_at":"2026-01-21T21:50:15.000Z","date":"2026-01-16","kind":"grant","planned":true,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest as follows: 25% on each of June 30, 2026? December 31, 2026? June 30, 2027? and December 31, 2027."}],"balance_after":65000,"derivative":{"exercise_price":3.04,"expiration_date":"2036-01-16","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001133416-26-000038","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000038/form4.xml","form_type":"4"}},{"id":934508,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69096,"kind":"person","name":"FREEMAN KEVIN D","position":1,"cik":"0001522478","reported_name":"FREEMAN KEVIN D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2026-01-21T21:49:30.000Z","date":"2026-01-16","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest 100% on December 31, 2026."}],"balance_after":60000,"derivative":{"exercise_price":3.04,"expiration_date":"2036-01-16","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001133416-26-000036","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000036/form4.xml","form_type":"4"}},{"id":934507,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":67287,"kind":"person","name":"ELDRED KARY","position":1,"cik":"0001543425","reported_name":"ELDRED KARY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2026-01-21T21:49:04.000Z","date":"2026-01-16","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest 100% on December 31, 2026."}],"balance_after":60000,"derivative":{"exercise_price":3.04,"expiration_date":"2036-01-16","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001133416-26-000034","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000034/form4.xml","form_type":"4"}},{"id":934506,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Unit","published_at":"2026-01-21T21:48:29.000Z","date":"2026-01-16","kind":"grant","planned":true,"acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The Restricted Stock Units, if vested, convert into Common Stock on a one for one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted Stock Units vest 100% on the earlier of December 31, 2026 or signing of a partnership agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted Stock Units vest 100% on the earlier of December 31, 2026 or signing of a partnership agreement."}],"balance_after":100000,"derivative":{"underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0001133416-26-000032","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000032/form4.xml","form_type":"4"}},{"id":934505,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock option (right to buy)","published_at":"2026-01-21T21:48:29.000Z","date":"2026-01-16","kind":"grant","planned":true,"acquired":true,"shares":84000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest as follows: 25% on each of June 30, 2026? December 31, 2026? June 30, 2027? and December 31, 2027."}],"balance_after":65000,"derivative":{"exercise_price":3.04,"expiration_date":"2036-01-16","underlying":"Common Stock","underlying_shares":84000},"source":{"system":"sec-edgar","filing":"0001133416-26-000032","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000032/form4.xml","form_type":"4"}},{"id":934504,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-01-21T21:47:42.000Z","date":"2026-01-16","kind":"grant","planned":true,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The Restricted Stock Units, if vested, convert into Common Stock on a one for one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted Stock Units vest 100% on the earlier of December 31, 2026 or signing of a partnership agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted Stock Units vest 100% on the earlier of December 31, 2026 or signing of a partnership agreement."}],"balance_after":100000,"derivative":{"underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001133416-26-000030","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000030/form4.xml","form_type":"4"}},{"id":934503,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock option (right to buy)","published_at":"2026-01-21T21:47:42.000Z","date":"2026-01-16","kind":"grant","planned":true,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest as follows: 25% on each of June 30, 2026? December 31, 2026? June 30, 2027? and December 31, 2027."}],"balance_after":65000,"derivative":{"exercise_price":3.04,"expiration_date":"2036-01-16","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001133416-26-000030","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000030/form4.xml","form_type":"4"}},{"id":934502,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2026-01-21T21:46:52.000Z","date":"2026-01-16","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest 100% on December 31, 2026."}],"balance_after":60000,"derivative":{"exercise_price":3.04,"expiration_date":"2036-01-16","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001133416-26-000028","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000028/form4.xml","form_type":"4"}},{"id":934501,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":12607,"kind":"person","name":"OMENN GILBERT S","position":1,"cik":"0001184227","reported_name":"OMENN GILBERT S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2026-01-21T21:46:12.000Z","date":"2026-01-16","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest 100% on December 31, 2026."}],"balance_after":60000,"derivative":{"exercise_price":0,"expiration_date":"2036-01-16","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001133416-26-000026","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000026/form4.xml","form_type":"4"}},{"id":934500,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":16647,"kind":"person","name":"AMELIO GILBERT F","position":1,"cik":"0001183247","reported_name":"AMELIO GILBERT F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2026-01-21T21:45:41.000Z","date":"2026-01-16","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest 100% on December 31, 2026."}],"balance_after":60000,"derivative":{"exercise_price":3.04,"expiration_date":"2036-01-16","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001133416-26-000024","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000024/form4.xml","form_type":"4"}},{"id":934499,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69094,"kind":"person","name":"Schwartz Elissa J.","position":1,"cik":"0001827177","reported_name":"Schwartz Elissa J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2026-01-21T21:44:58.000Z","date":"2026-01-16","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest 100% on December 31, 2026."}],"balance_after":60000,"derivative":{"exercise_price":3.04,"expiration_date":"2036-01-16","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001133416-26-000022","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000022/form4.xml","form_type":"4"}},{"id":934498,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock option (right to buy)","published_at":"2026-01-21T21:44:18.000Z","date":"2026-01-16","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest 100% on December 31, 2026."}],"balance_after":60000,"derivative":{"exercise_price":3.04,"expiration_date":"2036-01-16","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001133416-26-000020","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000020/form4.xml","form_type":"4"}},{"id":934497,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-01-21T21:44:18.000Z","date":"2026-01-16","kind":"grant","planned":false,"acquired":true,"shares":13158,"price":3.04,"value":40000.32,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"These restricted shares were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan in lieu of a cash retainer and meeting fees of $40,000 for 2026. Restrictions on the shares lapse at a rate of 25% at the end of each calendar quarter in 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"These restricted shares were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan in lieu of a cash retainer and meeting fees of $40,000 for 2026. Restrictions on the shares lapse at a rate of 25% at the end of each calendar quarter in 2026."}],"balance_after":10332676,"source":{"system":"sec-edgar","filing":"0001133416-26-000020","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000020/form4.xml","form_type":"4"}},{"id":940298,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-01-13T13:40:08.000Z","date":"2026-01-05","kind":"other","planned":true,"acquired":false,"shares":56332,"price":3.88,"value":218568.16,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020, amended on July 25, 2022. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be paid in the form of\ndeferred stock units (\"DSUs\") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis pursuant to the agreements, at a price per share equal to the closing\nprice of the Common Stock on date of the transaction. The DSUs from the amended agreement shall be settled in shares of Common Stock as follows: (i) fifty percent shall be settled on March 1, 2025 and (ii) fifty percent shall be settled on January 5, 2026."},{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares withheld from issuance to Mr. Lewis (but not sold) for federal and state withholding taxes on income."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents shares underlying DSUs and Common Stock."}],"balance_after":776260,"source":{"system":"sec-edgar","filing":"0001133416-26-000010","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000010/form4.xml","form_type":"4"}},{"id":947587,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Unit","published_at":"2026-01-06T21:54:53.000Z","date":"2026-01-02","kind":"exercise","planned":true,"acquired":false,"shares":84000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Shares of common stock acquired for no additional consideration resulting from vesting of Restricted Stock Units."},{"field":"shares","element":"transactionShares","label":"F5","text":"Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on January 2, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on January 2, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on January 2, 2026."}],"balance_after":0,"derivative":{"exercise_price":0,"exercise_date":"2026-01-01","underlying":"Common Stock","underlying_shares":84000},"source":{"system":"sec-edgar","filing":"0001133416-26-000008","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000008/form4.xml","form_type":"4"}},{"id":947586,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-01-06T21:54:53.000Z","date":"2026-01-06","kind":"sale","planned":true,"acquired":false,"shares":37698,"price":3.5772,"value":134853.2856,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"shares","element":"transactionShares","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The shares were sold in multiple transactions at prices ranging from $3.36 to $3.79.  This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":832592,"source":{"system":"sec-edgar","filing":"0001133416-26-000008","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000008/form4.xml","form_type":"4"}},{"id":947585,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-01-06T21:54:53.000Z","date":"2026-01-05","kind":"sale","planned":true,"acquired":false,"shares":27731,"price":3.9069,"value":108342.2439,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"shares","element":"transactionShares","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The shares were sold in multiple transactions at prices ranging from $3.81 to $4.06.  This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":870290,"source":{"system":"sec-edgar","filing":"0001133416-26-000008","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000008/form4.xml","form_type":"4"}},{"id":947584,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-01-06T21:54:53.000Z","date":"2026-01-02","kind":"sale","planned":true,"acquired":false,"shares":18571,"price":4.1968,"value":77938.7728,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"shares","element":"transactionShares","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The shares were sold in multiple transactions at prices ranging from $4.00 to $4.34.  This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":898021,"source":{"system":"sec-edgar","filing":"0001133416-26-000008","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000008/form4.xml","form_type":"4"}},{"id":947583,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-01-06T21:54:53.000Z","date":"2026-01-02","kind":"exercise","planned":true,"acquired":true,"shares":84000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Shares of common stock acquired for no additional consideration resulting from vesting of Restricted Stock Units."}],"balance_after":916592,"source":{"system":"sec-edgar","filing":"0001133416-26-000008","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000008/form4.xml","form_type":"4"}},{"id":947582,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-01-06T21:54:05.000Z","date":"2026-01-01","kind":"exercise","planned":true,"acquired":false,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Shares of common stock acquired for no additional consideration resulting from vesting of Restricted Stock Units."},{"field":"shares","element":"transactionShares","label":"F4","text":"Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on January 2, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on January 2, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on January 2, 2026."}],"balance_after":0,"derivative":{"exercise_price":0,"exercise_date":"2026-01-02","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001133416-26-000006","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000006/form4.xml","form_type":"4"}},{"id":947581,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-06T21:54:05.000Z","date":"2026-01-06","kind":"sale","planned":true,"acquired":false,"shares":20354,"price":3.6698,"value":74695.1092,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"shares","element":"transactionShares","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The shares were sold in multiple transactions at prices ranging from $3.47 to $3.81. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":7614,"source":{"system":"sec-edgar","filing":"0001133416-26-000006","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000006/form4.xml","form_type":"4"}},{"id":947580,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-06T21:54:05.000Z","date":"2026-01-05","kind":"sale","planned":true,"acquired":false,"shares":25732,"price":3.8978,"value":100298.1896,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"shares","element":"transactionShares","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The shares were sold in multiple transactions at prices ranging from $3.81 to $4.06. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":27968,"source":{"system":"sec-edgar","filing":"0001133416-26-000006","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000006/form4.xml","form_type":"4"}},{"id":947579,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-06T21:54:05.000Z","date":"2026-01-02","kind":"sale","planned":true,"acquired":false,"shares":13914,"price":4.1968,"value":58394.2752,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"shares","element":"transactionShares","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple transactions at prices ranging from $4.00 to $4.34. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":53700,"source":{"system":"sec-edgar","filing":"0001133416-26-000006","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000006/form4.xml","form_type":"4"}},{"id":947578,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-06T21:54:05.000Z","date":"2026-01-02","kind":"exercise","planned":true,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Shares of common stock acquired for no additional consideration resulting from vesting of Restricted Stock Units."}],"balance_after":67614,"source":{"system":"sec-edgar","filing":"0001133416-26-000006","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000006/form4.xml","form_type":"4"}},{"id":947577,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-01-06T21:53:32.000Z","date":"2026-01-01","kind":"exercise","planned":true,"acquired":false,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Shares of common stock acquired for no additional consideration resulting from vesting of Restricted Stock Units."},{"field":"shares","element":"transactionShares","label":"F4","text":"Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on January 2, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on January 2, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on January 2, 2026."}],"balance_after":0,"derivative":{"exercise_price":0,"exercise_date":"2026-01-02","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001133416-26-000004","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000004/form4.xml","form_type":"4"}},{"id":947576,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-01-06T21:53:32.000Z","date":"2026-01-06","kind":"sale","planned":true,"acquired":false,"shares":21446,"price":3.6466,"value":78204.9836,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"shares","element":"transactionShares","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The shares were sold in multiple transactions at prices ranging from $3.81 to $3.42. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001133416-26-000004","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000004/form4.xml","form_type":"4"}},{"id":947575,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2026-01-06T21:53:32.000Z","date":"2026-01-05","kind":"sale","planned":true,"acquired":false,"shares":25499,"price":3.8985,"value":99407.8515,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"shares","element":"transactionShares","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The shares were sold in multiple transactions at prices ranging from $3.81 to $4.06. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":21446,"source":{"system":"sec-edgar","filing":"0001133416-26-000004","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000004/form4.xml","form_type":"4"}},{"id":947574,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-01-06T21:53:32.000Z","date":"2026-01-02","kind":"sale","planned":true,"acquired":false,"shares":13055,"price":4.1968,"value":54789.224,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"shares","element":"transactionShares","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple transactions at prices ranging from $4.00 to $4.34. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":46945,"source":{"system":"sec-edgar","filing":"0001133416-26-000004","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000004/form4.xml","form_type":"4"}},{"id":947573,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-01-06T21:53:32.000Z","date":"2026-01-02","kind":"exercise","planned":true,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Shares of common stock acquired for no additional consideration resulting from vesting of Restricted Stock Units."}],"balance_after":60000,"source":{"system":"sec-edgar","filing":"0001133416-26-000004","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000004/form4.xml","form_type":"4"}},{"id":952675,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock option (right to buy)","published_at":"2026-01-05T21:07:55.000Z","date":"2025-12-31","kind":"exercise","planned":true,"acquired":false,"shares":8125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vest as follows: 16,250  on each of June 30, 2025, December 31, 2025, June 30, 2026, and December 31, 2026."}],"balance_after":40625,"derivative":{"exercise_price":1.23,"exercise_date":"2025-12-31","expiration_date":"2035-01-23","underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001133416-26-000002","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000002/form4.xml","form_type":"4"}},{"id":952674,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-01-05T21:07:55.000Z","date":"2025-12-31","kind":"sale","planned":true,"acquired":false,"shares":8125,"price":4.0725,"value":33089.0625,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple transactions at prices ranging from $4.00 to $4.15. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001133416-26-000002","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000002/form4.xml","form_type":"4"}},{"id":952673,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-01-05T21:07:55.000Z","date":"2025-12-31","kind":"exercise","planned":true,"acquired":true,"shares":8125,"price":1.23,"value":9993.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."}],"balance_after":8125,"source":{"system":"sec-edgar","filing":"0001133416-26-000002","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000002/form4.xml","form_type":"4"}},{"id":959971,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69096,"kind":"person","name":"FREEMAN KEVIN D","position":1,"cik":"0001522478","reported_name":"FREEMAN KEVIN D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-23T18:21:11.000Z","date":"2025-12-23","kind":"purchase","planned":false,"acquired":true,"shares":5500,"price":3.548,"value":19514.0,"ownership":{"direct":true},"balance_after":55269,"source":{"system":"sec-edgar","filing":"0001133416-25-000081","document":"form4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000081/form4a.xml","form_type":"4/A","original_submission_date":"2025-12-23"}},{"id":959970,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69096,"kind":"person","name":"FREEMAN KEVIN D","position":1,"cik":"0001522478","reported_name":"FREEMAN KEVIN D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-23T18:19:30.000Z","date":"2025-12-23","kind":"purchase","planned":true,"acquired":true,"shares":5500,"price":3.548,"value":19514.0,"ownership":{"direct":true},"balance_after":55269,"source":{"system":"sec-edgar","filing":"0001133416-25-000080","document":"form4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000080/form4a.xml","form_type":"4/A","original_submission_date":"2025-12-23"}},{"id":959969,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":67287,"kind":"person","name":"ELDRED KARY","position":1,"cik":"0001543425","reported_name":"ELDRED KARY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-23T18:17:21.000Z","date":"2025-12-23","kind":"purchase","planned":false,"acquired":true,"shares":700,"price":3.73,"value":2611.0,"ownership":{"direct":true},"balance_after":65382,"source":{"system":"sec-edgar","filing":"0001133416-25-000078","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000078/form4.xml","form_type":"4"}},{"id":959968,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69096,"kind":"person","name":"FREEMAN KEVIN D","position":1,"cik":"0001522478","reported_name":"FREEMAN KEVIN D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-23T16:29:19.000Z","date":"2025-12-23","kind":"purchase","planned":true,"acquired":true,"shares":5500,"price":3.548,"value":19514.0,"ownership":{"direct":true},"balance_after":55269,"source":{"system":"sec-edgar","filing":"0001133416-25-000075","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000075/form4.xml","form_type":"4"}},{"id":959967,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":67287,"kind":"person","name":"ELDRED KARY","position":1,"cik":"0001543425","reported_name":"ELDRED KARY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-23T16:28:55.000Z","date":"2025-12-23","kind":"purchase","planned":true,"acquired":true,"shares":700,"price":3.73,"value":2611.0,"ownership":{"direct":true},"balance_after":65382,"source":{"system":"sec-edgar","filing":"0001133416-25-000074","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000074/form4.xml","form_type":"4"}},{"id":962324,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock option (right to buy)","published_at":"2025-12-19T21:08:14.000Z","date":"2025-12-17","kind":"exercise","planned":true,"acquired":false,"shares":7829,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the\nSEC on August 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vested 100% on December 31, 2020."}],"balance_after":32171,"derivative":{"exercise_price":2.86,"exercise_date":"2020-12-31","expiration_date":"2030-01-09","underlying":"Common Stock","underlying_shares":7829},"source":{"system":"sec-edgar","filing":"0001133416-25-000071","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000071/form4.xml","form_type":"4"}},{"id":962323,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-12-19T21:08:14.000Z","date":"2025-12-17","kind":"sale","planned":true,"acquired":false,"shares":7829,"price":7.056,"value":55241.424,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the\nSEC on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The shares were sold in multiple transactions at prices ranging from $7.00 to $7.11.  This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":832592,"source":{"system":"sec-edgar","filing":"0001133416-25-000071","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000071/form4.xml","form_type":"4"}},{"id":962322,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69019,"kind":"person","name":"LEWIS JOEL","position":1,"cik":"0001725595","reported_name":"LEWIS JOEL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-12-19T21:08:14.000Z","date":"2025-12-17","kind":"exercise","planned":true,"acquired":true,"shares":7829,"price":2.86,"value":22390.94,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the\nSEC on August 14, 2025."}],"balance_after":840421,"source":{"system":"sec-edgar","filing":"0001133416-25-000071","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000071/form4.xml","form_type":"4"}},{"id":962321,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock option (right to buy)","published_at":"2025-12-19T21:06:14.000Z","date":"2025-12-17","kind":"exercise","planned":true,"acquired":false,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vest as follows: 25,000 on each of October 31, 2024, January 31, 2025, April 30, 2025, and July 31, 2025."}],"balance_after":50000,"derivative":{"exercise_price":2.5,"exercise_date":"2025-07-31","expiration_date":"2034-08-01","underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001133416-25-000069","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000069/form4.xml","form_type":"4"}},{"id":962320,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock option (right to buy)","published_at":"2025-12-19T21:06:14.000Z","date":"2025-12-17","kind":"exercise","planned":true,"acquired":false,"shares":6463,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vest as follows: 50,000 on March 11, 2025, with 50,000 scheduled to vest on each of March 11, 2026 and March 11, 2027."}],"balance_after":102037,"derivative":{"exercise_price":2.2,"exercise_date":"2025-03-31","expiration_date":"2034-03-20","underlying":"Common Stock","underlying_shares":6364},"source":{"system":"sec-edgar","filing":"0001133416-25-000069","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000069/form4.xml","form_type":"4"}},{"id":962319,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-12-19T21:06:14.000Z","date":"2025-12-17","kind":"sale","planned":true,"acquired":false,"shares":8500,"price":7.04,"value":59840.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple transactions at prices ranging from $7.00 to $7.11. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001133416-25-000069","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000069/form4.xml","form_type":"4"}},{"id":962318,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-12-19T21:06:14.000Z","date":"2025-12-17","kind":"exercise","planned":true,"acquired":true,"shares":8500,"price":2.5,"value":21250.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."}],"balance_after":8500,"source":{"system":"sec-edgar","filing":"0001133416-25-000069","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000069/form4.xml","form_type":"4"}},{"id":962317,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-12-19T21:06:14.000Z","date":"2025-12-17","kind":"sale","planned":true,"acquired":false,"shares":6463,"price":7.04,"value":45499.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple transactions at prices ranging from $7.00 to $7.11. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001133416-25-000069","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000069/form4.xml","form_type":"4"}},{"id":962316,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-12-19T21:06:14.000Z","date":"2025-12-17","kind":"exercise","planned":true,"acquired":true,"shares":6463,"price":2.2,"value":14218.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."}],"balance_after":6463,"source":{"system":"sec-edgar","filing":"0001133416-25-000069","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000069/form4.xml","form_type":"4"}},{"id":962315,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-12-19T21:06:14.000Z","date":"2025-12-17","kind":"sale","planned":true,"acquired":false,"shares":4479,"price":7.04,"value":31532.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple transactions at prices ranging from $7.00 to $7.11. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001133416-25-000069","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000069/form4.xml","form_type":"4"}},{"id":962314,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-12-19T21:05:11.000Z","date":"2025-12-17","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vested 100% on December 31, 2022.."}],"balance_after":0,"derivative":{"exercise_price":1.98,"exercise_date":"2022-12-31","expiration_date":"2032-01-24","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001133416-25-000067","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000067/form4.xml","form_type":"4"}},{"id":962313,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-19T21:05:11.000Z","date":"2025-12-17","kind":"sale","planned":true,"acquired":false,"shares":4706,"price":7.038,"value":33120.828,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple transactions at prices ranging from $7.11 to $7.11. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":6500,"source":{"system":"sec-edgar","filing":"0001133416-25-000067","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000067/form4.xml","form_type":"4"}},{"id":962312,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-19T21:05:11.000Z","date":"2025-12-17","kind":"sale","planned":true,"acquired":false,"shares":19793,"price":7.038,"value":139303.134,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple transactions at prices ranging from $7.11 to $7.11. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":11206,"source":{"system":"sec-edgar","filing":"0001133416-25-000067","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000067/form4.xml","form_type":"4"}},{"id":962311,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-19T21:05:11.000Z","date":"2025-12-17","kind":"exercise","planned":true,"acquired":true,"shares":20000,"price":1.98,"value":39600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."}],"balance_after":31206,"source":{"system":"sec-edgar","filing":"0001133416-25-000067","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000067/form4.xml","form_type":"4"}},{"id":963454,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71219,"kind":"organization","name":"10X Fund, L.P.","position":1,"cik":"0001453356","reported_name":"10X Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71220,"kind":"organization","name":"10X Capital Management, LLC","position":2,"cik":"0001457247","reported_name":"10X Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":3,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-12-18T15:34:54.000Z","date":"2025-12-16","kind":"sale","planned":false,"acquired":false,"shares":30681,"price":6.66,"value":204335.46,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The shares were sold in multiple transactions at prices ranging from $6.64 to $6.69. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":5614457,"source":{"system":"sec-edgar","filing":"0001493152-25-028303","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315225028303/ownership.xml","form_type":"4"}},{"id":963453,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71219,"kind":"organization","name":"10X Fund, L.P.","position":1,"cik":"0001453356","reported_name":"10X Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71220,"kind":"organization","name":"10X Capital Management, LLC","position":2,"cik":"0001457247","reported_name":"10X Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":3,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-12-18T15:34:54.000Z","date":"2025-11-24","kind":"other","planned":false,"acquired":false,"shares":24000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were distributed in an in-kind distribution to a withdrawing limited partner of 10X Fund, LP of his/her/its pro rata share of shares held by 10X Fund, LP, which did not receive any consideration for the transfer. The distribution is exempt from Section 16(b) because it does not constitute a sale of a security under applicable law."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares were distributed in an in-kind distribution to a withdrawing limited partner of 10X Fund, LP of his/her/its pro rata share of shares held by 10X Fund, LP, which did not receive any consideration for the transfer. The distribution is exempt from Section 16(b) because it does not constitute a sale of a security under applicable law."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":5645138,"source":{"system":"sec-edgar","filing":"0001493152-25-028303","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315225028303/ownership.xml","form_type":"4"}},{"id":968014,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2025-12-16T21:22:54.000Z","date":"2025-12-15","kind":"exercise","planned":true,"acquired":false,"shares":8417,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vested as follows: 25% on each of June 30, 2018 and September 30, 2018, and 50% on December 31, 2018."}],"balance_after":0,"derivative":{"exercise_price":4.16,"exercise_date":"2018-12-31","expiration_date":"2028-05-22","underlying":"Common Stock","underlying_shares":8417},"source":{"system":"sec-edgar","filing":"0001133416-25-000064","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000064/form4.xml","form_type":"4"}},{"id":968013,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-12-16T21:22:54.000Z","date":"2025-12-12","kind":"exercise","planned":true,"acquired":false,"shares":19793,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vested as follows: 25% on each of June 30, 2018 and September 30, 2018, and 50% on December 31, 2018."}],"balance_after":53417,"derivative":{"exercise_price":4.16,"exercise_date":"2018-12-31","expiration_date":"2028-05-22","underlying":"Common Stock","underlying_shares":16790},"source":{"system":"sec-edgar","filing":"0001133416-25-000064","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000064/form4.xml","form_type":"4"}},{"id":968012,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-16T21:22:54.000Z","date":"2025-12-15","kind":"sale","planned":true,"acquired":false,"shares":8417,"price":6.3,"value":53027.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple transactions at prices ranging from $6.25 to $6.40. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":11206,"source":{"system":"sec-edgar","filing":"0001133416-25-000064","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000064/form4.xml","form_type":"4"}},{"id":968011,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stok","published_at":"2025-12-16T21:22:54.000Z","date":"2025-12-15","kind":"exercise","planned":true,"acquired":true,"shares":8417,"price":4.16,"value":35014.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."}],"balance_after":19623,"source":{"system":"sec-edgar","filing":"0001133416-25-000064","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000064/form4.xml","form_type":"4"}},{"id":968010,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-16T21:22:54.000Z","date":"2025-12-12","kind":"sale","planned":true,"acquired":false,"shares":19793,"price":6.274,"value":124181.282,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple transactions at prices ranging from $6.25 to $6.40. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":11206,"source":{"system":"sec-edgar","filing":"0001133416-25-000064","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000064/form4.xml","form_type":"4"}},{"id":968009,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-16T21:22:54.000Z","date":"2025-12-12","kind":"exercise","planned":true,"acquired":true,"shares":19793,"price":4.16,"value":82338.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."}],"balance_after":30999,"source":{"system":"sec-edgar","filing":"0001133416-25-000064","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000064/form4.xml","form_type":"4"}},{"id":974841,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-12-10T13:15:55.000Z","date":"2025-12-09","kind":"exercise","planned":true,"acquired":false,"shares":16790,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The options vested as follows: 25% on each of June 30, 2018 and September 30, 2018, and 50% on December 31, 2018."}],"balance_after":73210,"derivative":{"exercise_price":4.16,"exercise_date":"2018-12-31","expiration_date":"2028-05-22","underlying":"Common Stock","underlying_shares":16790},"source":{"system":"sec-edgar","filing":"0001133416-25-000061","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000061/form4.xml","form_type":"4"}},{"id":974840,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-12-10T13:15:55.000Z","date":"2025-12-08","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The options vested 100% on December 31, 2023."}],"balance_after":20000,"derivative":{"exercise_price":1.11,"exercise_date":"2023-12-31","expiration_date":"2033-01-26","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001133416-25-000061","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000061/form4.xml","form_type":"4"}},{"id":974839,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-12-10T13:15:55.000Z","date":"2025-12-08","kind":"exercise","planned":true,"acquired":false,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The options vested 100% on December 31, 2024."}],"balance_after":35000,"derivative":{"exercise_price":2.11,"exercise_date":"2024-12-31","expiration_date":"2031-03-25","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001133416-25-000061","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000061/form4.xml","form_type":"4"}},{"id":974838,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-12-10T13:15:55.000Z","date":"2025-12-08","kind":"exercise","planned":true,"acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The options vested 100% on December 31, 2024."}],"balance_after":25000,"derivative":{"exercise_price":1.72,"exercise_date":"2024-12-31","expiration_date":"2034-01-24","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001133416-25-000061","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000061/form4.xml","form_type":"4"}},{"id":974837,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2025-12-10T13:15:55.000Z","date":"2025-12-08","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vested 100% on December 31, 2022."}],"balance_after":20000,"derivative":{"exercise_price":1.98,"exercise_date":"2022-12-31","expiration_date":"2032-01-24","underlying":"Common stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001133416-25-000061","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000061/form4.xml","form_type":"4"}},{"id":974836,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2025-12-10T13:15:55.000Z","date":"2025-12-08","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vested 100% on December 31, 2021."}],"balance_after":20000,"derivative":{"exercise_price":2.11,"exercise_date":"2021-12-31","expiration_date":"2031-03-25","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001133416-25-000061","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000061/form4.xml","form_type":"4"}},{"id":974835,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2025-12-10T13:15:55.000Z","date":"2025-12-08","kind":"exercise","planned":true,"acquired":false,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vested as follows: 25% on each of June 30, 2021, December 31, 2021, June 30, 2022, and December 31, 2022."}],"balance_after":35000,"derivative":{"exercise_price":2.86,"exercise_date":"2021-12-31","expiration_date":"2031-03-25","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001133416-25-000061","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000061/form4.xml","form_type":"4"}}],"next_cursor":"2025-12-10T13:15:55.000000Z,974835"}